Showing results (1541-1550 of 1,879) with videos related to
Sort By:
Pageof 188
Immunotherapy|April 5, 2019
Efficacy of dendritic cell-based immunotherapy produced from cord blood in vitro and in a humanized NSG mouse cancer modelGang Liu, Xiaoyan Fan, Ying Cai, et al.Immunotherapy|February 5, 2014
Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disordersVeronica Lindström, Elisabet Ihse, Therese Fagerqvist, et al.Immunotherapy|February 5, 2014
Emerging immunotherapy strategies in breast cancerDavid B Page, Jarushka Naidoo, Heather L McArthurImmunotherapy|August 30, 2019
Bullous pemphigoid associated with the 480-mg nivolumab dose in a patient with metastatic renal cell carcinomaAmruth Ratnakar Palla, Emily Smith, Donald DollImmunotherapy|September 4, 2019
Essential role of CD4+ T cells for the activation of group 2 innate lymphoid cells during respiratory syncytial virus infection in miceXu Han, Song Bai, Yulin Cui, et al.Immunotherapy|September 4, 2019
Natural killer cell-based immunotherapy with CTLA4Ig-primed donor lymphocytes following haploidentical transplantationSarita Rani Jaiswal, Suparno ChakrabartiImmunotherapy|September 4, 2019
Granuloma-like lesion at subcutaneous immunoglobulin site in a common variable immunodeficiency patientAnkmalika Gupta, Beverly Wang, Sudhir GuptaImmunotherapy|April 29, 2015
IL-11 signaling as a therapeutic target for cancerTracy L Putoczki, Matthias ErnstImmunotherapy|September 5, 2025
First-line pembrolizumab for metastatic NSCLC in lower-middle-income countries: bridging the efficacy-effectiveness gapUllas Batra, Mansi Sharma, Alexis Andrew Miller, et al.Immunotherapy|August 4, 2016
A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarkerPedro N Aguiar, Ilka Lopes Santoro, Hakaru Tadokoro, et al.Pageof 188